Retour

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

Calendar Calendar of Events

SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.

GlobeNewswire Inc. • 07/05/2024 à 13:00:00
Nurix Therapeutics, Inc. Common stock
Address: 1700 OWENS STREET, SUITE 205
Postal Code: 94158
City: SAN FRANCISCO
State: CA
Phone Number: (415) 660-5320
Website: http://www.nurixtx.com
Status: Active
Company Info

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

List Date2020-07-24
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001549595
Composite figiBBG00SDJ8M78
Share Class figiBBG00SDJ8M87
Market Cap1,013,109,178 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees284
Share Class Shares Outstanding59320000
Weighted Shares Outstanding61067461
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
16.575
15.56
15.9
15.415
14.03
Variance
6.52%
-2.14%
6.3%
9.87%
5.73%
Open
15.56
15.9
14.958
14.03
13.27
Highest
16.82
16.005
16.564
15.415
14.03
Lowest
16.812
15.967
16.548
15.415
14.03
History
PeriodVarhighestlowest
1 week
24.91%
14.03
14.03
1 month
23.01%
14.07
12.461
3 month
69.5%
10.134
10.08
6 month
162.68%
6.805
5.65
1 year
67.42%
10.14
4.22
3 year
-34.97%
26.42
4.22
5 year
-8.22%
21.3295
4.22
10 year
-8.22%
21.3295
4.22
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-04-13 2023-07-13 2023-10-12 UNPUB
Assets 370,154,000 350,624,000 308,195,000 UNPUB
Current Assets 288,329,000 290,014,000 267,949,000 UNPUB
Current Liabilities 64,878,000 72,262,000 61,493,000 UNPUB
Equity 274,052,000 259,921,000 233,817,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 274,052,000 259,921,000 233,817,000 UNPUB
Liabilities 96,102,000 90,703,000 74,378,000 UNPUB
Liabilities And Equity 370,154,000 350,624,000 308,195,000 UNPUB
Noncurrent Assets 81,825,000 60,610,000 40,246,000 UNPUB
Noncurrent Liabilities 0 18,441,000 12,885,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-04-13 2023-07-13 2023-10-12 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -30,903,000 25,387,000 -16,654,000 UNPUB
Net Cash Flow, Continuing -30,903,000 25,387,000 -16,654,000 UNPUB
Net Cash Flow From Financing Activities 1,481,000 25,000 1,704,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 1,481,000 25,000 1,704,000 UNPUB
Net Cash Flow From Investing Activities 16,068,000 43,831,000 22,775,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 16,068,000 43,831,000 22,775,000 UNPUB
Net Cash Flow From Operating Activities -48,452,000 -18,469,000 -41,133,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -48,452,000 -18,469,000 -41,133,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-04-13 2023-07-13 2023-10-12 UNPUB
Comprehensive Income/Loss -40,733,000 -22,933,000 -36,307,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -39,661,000 -22,933,000 -36,307,000 UNPUB
Other Comprehensive Income/Loss 0 -22,933,000 -36,307,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-04-13 2023-07-13 2023-10-12 UNPUB
Basic Earnings Per Share -1 0 -1 UNPUB
Benefits Costs and Expenses 0 0 0 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 55,637,000 57,441,000 58,479,000 UNPUB
Diluted Earnings Per Share -1 0 -1 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -40,733,000 -24,277,000 -36,982,000 UNPUB
Income/Loss From Continuing Operations Before Tax -40,733,000 30,676,000 18,467,000 UNPUB
Income Tax Expense/Benefit 0 0 0 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -40,733,000 -24,277,000 -36,982,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -40,733,000 -24,277,000 -36,982,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -40,733,000 -24,277,000 -36,982,000 UNPUB
Operating Expenses 55,637,000 57,441,000 58,479,000 UNPUB
Operating Income/Loss -42,952,000 -26,765,000 -40,012,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 12,685,000 30,676,000 18,467,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-04-08 2022-07-07 2022-10-06 2023-02-09
Assets 437,720,000 394,310,000 459,338,000 416,759,000
Current Assets 280,484,000 306,789,000 354,871,000 318,449,000
Current Liabilities 66,049,000 72,665,000 67,500,000 70,655,000
Equity 305,917,000 266,739,000 342,545,000 303,696,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 305,917,000 266,739,000 342,545,000 303,696,000
Liabilities 131,803,000 127,571,000 116,793,000 113,063,000
Liabilities And Equity 437,720,000 394,310,000 459,338,000 416,759,000
Noncurrent Assets 157,236,000 87,521,000 104,467,000 98,310,000
Noncurrent Liabilities 0 0 49,293,000 42,408,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-04-08 2022-07-07 2022-10-06 2023-02-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -1,111,000 -37,247,000 6,023,000 -15,417,000
Net Cash Flow, Continuing -1,111,000 -37,247,000 6,023,000 -15,417,000
Net Cash Flow From Financing Activities 1,488,000 432,000 115,407,000 117,192,000
Net Cash Flow From Financing Activities, Continuing 1,488,000 432,000 115,407,000 117,192,000
Net Cash Flow From Investing Activities 40,031,000 -4,765,000 -63,076,000 27,198,000
Net Cash Flow From Investing Activities, Continuing 40,031,000 -4,765,000 -63,076,000 27,198,000
Net Cash Flow From Operating Activities -42,630,000 -32,914,000 -46,308,000 -159,807,000
Net Cash Flow From Operating Activities, Continuing -42,630,000 -32,914,000 -46,308,000 -159,807,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-04-08 2022-07-07 2022-10-06 2023-02-09
Comprehensive Income/Loss -42,533,000 -45,401,000 -46,366,000 -184,071,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -43,991,000 -46,420,000 -46,366,000 -184,071,000
Other Comprehensive Income/Loss 0 0 -46,366,000 -184,071,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-04-08 2022-07-07 2022-10-06 2023-02-09
Basic Earnings Per Share -1 -1 -1 -4
Benefits Costs and Expenses 52,154,000 56,833,000 56,500,000 218,987,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 52,154,000 56,833,000 56,500,000 218,987,000
Diluted Earnings Per Share -1 -1 -1 -4
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -42,533,000 -45,401,000 -45,709,000 -180,360,000
Income/Loss From Continuing Operations Before Tax -42,533,000 -45,401,000 -45,709,000 -180,360,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -42,533,000 -45,401,000 -45,709,000 -180,360,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -42,533,000 -45,401,000 -45,709,000 -180,360,000
Net Income/Loss Available To Common Stockholders, Basic -42,533,000 -45,401,000 -45,709,000 -180,360,000
Operating Expenses 52,365,000 57,147,000 57,509,000 222,494,000
Operating Income/Loss -42,744,000 -45,715,000 -46,718,000 -183,867,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 9,621,000 11,432,000 10,791,000 38,627,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-04-13 2021-07-13 2021-10-14 2022-01-28
Assets 396,660,000 517,981,000 493,074,000 476,771,000
Current Assets 310,768,000 396,281,000 358,445,000 311,118,000
Current Liabilities 47,972,000 46,844,000 50,680,000 66,258,000
Equity 270,133,000 398,178,000 375,217,000 342,302,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 270,133,000 398,178,000 375,217,000 342,302,000
Liabilities 126,527,000 119,803,000 117,857,000 134,469,000
Liabilities And Equity 396,660,000 517,981,000 493,074,000 476,771,000
Noncurrent Assets 85,892,000 121,700,000 134,629,000 165,653,000
Noncurrent Liabilities 0 0 67,177,000 68,211,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-04-13 2021-07-13 2021-10-14 2022-01-28
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 7,025,000 61,826,000 -40,651,000 -38,734,000
Net Cash Flow, Continuing 7,025,000 61,826,000 -40,651,000 -38,734,000
Net Cash Flow From Financing Activities 1,359,000 150,471,000 1,552,000 153,882,000
Net Cash Flow From Financing Activities, Continuing 1,359,000 150,471,000 1,552,000 153,882,000
Net Cash Flow From Investing Activities -2,387,000 -57,110,000 -12,231,000 -108,251,000
Net Cash Flow From Investing Activities, Continuing -2,387,000 -57,110,000 -12,231,000 -108,251,000
Net Cash Flow From Operating Activities 8,053,000 -31,535,000 -29,972,000 -84,365,000
Net Cash Flow From Operating Activities, Continuing 8,053,000 -31,535,000 -29,972,000 -84,365,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-04-13 2021-07-13 2021-10-14 2022-01-28
Comprehensive Income/Loss -24,275,000 -26,382,000 -28,924,000 -117,889,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -24,313,000 -26,401,000 -28,924,000 -117,889,000
Other Comprehensive Income/Loss 0 0 -28,924,000 -695,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-04-13 2021-07-13 2021-10-14 2022-01-28
Basic Earnings Per Share -1 -1 UNPUB UNPUB
Benefits Costs and Expenses 29,215,000 33,334,000 39,210,000 146,813,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 29,215,000 33,334,000 39,210,000 146,813,000
Diluted Earnings Per Share -1 -1 UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -24,275,000 -26,382,000 -28,835,000 -117,194,000
Income/Loss From Continuing Operations Before Tax -24,204,000 -26,243,000 -28,958,000 -117,063,000
Income Tax Expense/Benefit 71,000 139,000 -123,000 131,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -24,275,000 -26,382,000 -28,835,000 -117,194,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -24,275,000 -26,382,000 -28,835,000 -117,194,000
Net Income/Loss Available To Common Stockholders, Basic -24,275,000 -26,382,000 -28,835,000 -117,194,000
Operating Expenses 29,533,000 33,505,000 39,249,000 147,636,000
Operating Income/Loss -24,522,000 -26,414,000 -28,997,000 -117,886,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 5,011,000 7,091,000 10,252,000 29,750,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-10-14 2021-02-16
Assets UNPUB UNPUB 411,874,000 396,343,000
Current Assets UNPUB UNPUB 364,089,000 298,434,000
Current Liabilities UNPUB UNPUB 41,012,000 44,539,000
Equity UNPUB UNPUB 307,620,000 290,269,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 307,620,000 290,269,000
Liabilities UNPUB UNPUB 104,254,000 106,074,000
Liabilities And Equity UNPUB UNPUB 411,874,000 396,343,000
Noncurrent Assets UNPUB UNPUB 47,785,000 97,909,000
Noncurrent Liabilities UNPUB UNPUB 63,242,000 61,535,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-10-14 2021-02-16
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB UNPUB 84,540,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 84,540,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 339,024,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 339,024,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -254,404,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -254,404,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -80,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -80,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-10-14 2021-02-16
Comprehensive Income/Loss UNPUB UNPUB -18,517,000 -43,153,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -18,518,000 -43,153,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 89,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-10-14 2021-02-16
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB 0 81,597,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 0 81,597,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -18,517,000 -43,242,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -18,517,000 -63,777,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB -20,535,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -18,517,000 -43,242,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -18,517,000 -43,242,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -18,517,000 -43,242,000
Operating Expenses UNPUB UNPUB 23,277,000 82,803,000
Operating Income/Loss UNPUB UNPUB -19,192,000 -64,983,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 4,085,000 17,820,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:NRIX240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:NRIX240517P00022500 OPASPS Put American 100 22.5 BATO 2024-05-17
O:NRIX240517P00020000 OPASPS Put American 100 20 BATO 2024-05-17
O:NRIX240517P00017500 OPASPS Put American 100 17.5 BATO 2024-05-17
O:NRIX240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:NRIX240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:NRIX240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:NRIX240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:NRIX240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:NRIX240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:NRIX240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:NRIX240517C00022500 OCASPS Call American 100 22.5 BATO 2024-05-17
O:NRIX240517C00020000 OCASPS Call American 100 20 BATO 2024-05-17
O:NRIX240517C00017500 OCASPS Call American 100 17.5 BATO 2024-05-17
O:NRIX240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:NRIX240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:NRIX240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:NRIX240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:NRIX240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:NRIX240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:NRIX240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:NRIX240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:NRIX240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:NRIX240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:NRIX240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:NRIX240419C00017500 OCASPS Call American 100 17.5 BATO 2024-04-19
O:NRIX240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:NRIX240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:NRIX240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:NRIX240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:NRIX240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:NRIX240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:NRIX240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:NRIX240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:NRIX240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:NRIX240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:NRIX240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:NRIX240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:NRIX240419P00017500 OPASPS Put American 100 17.5 BATO 2024-04-19
O:NRIX240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:NRIX240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:NRIX240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:NRIX240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:NRIX240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:NRIX240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:NRIX240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:NRIX240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:NRIX240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:NRIX240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:NRIX240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:NRIX240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:NRIX240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:NRIX240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:NRIX240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:NRIX240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:NRIX240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:NRIX240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:NRIX240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:NRIX240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:NRIX240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:NRIX240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:NRIX240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:NRIX240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:NRIX240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:NRIX240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:NRIX240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:NRIX240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:NRIX240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:NRIX240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:NRIX240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:NRIX240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:NRIX240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:NRIX240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:NRIX240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:NRIX240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:NRIX240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:NRIX240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:NRIX240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:NRIX240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:NRIX240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:NRIX240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:NRIX240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:NRIX240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:NRIX240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:NRIX240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:NRIX240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:NRIX240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:NRIX240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:NRIX240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:NRIX240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:NRIX240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:NRIX240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:NRIX240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:NRIX240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:NRIX240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:NRIX240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:NRIX240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:NRIX240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:NRIX240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:NRIX240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:NRIX231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:NRIX231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:NRIX231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:NRIX231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:NRIX231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:NRIX231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:NRIX231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:NRIX231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:NRIX231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:NRIX231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:NRIX231117P00017500 OPASPS Put American 100 17.5 BATO 2023-11-17
O:NRIX231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:NRIX231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:NRIX231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:NRIX231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:NRIX231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:NRIX231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:NRIX231117C00017500 OCASPS Call American 100 17.5 BATO 2023-11-17
O:NRIX231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:NRIX231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:NRIX231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:NRIX231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:NRIX231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:NRIX231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:NRIX231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:NRIX231020P00020000 OPASPS Put American 100 20 BATO 2023-10-20
O:NRIX231020P00017500 OPASPS Put American 100 17.5 BATO 2023-10-20
O:NRIX231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:NRIX231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:NRIX231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:NRIX231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:NRIX231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:NRIX231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:NRIX231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:NRIX231020C00020000 OCASPS Call American 100 20 BATO 2023-10-20
O:NRIX231020C00017500 OCASPS Call American 100 17.5 BATO 2023-10-20
O:NRIX231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:NRIX231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:NRIX231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:NRIX231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:NRIX231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:NRIX231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:NRIX230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:NRIX230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:NRIX230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:NRIX230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:NRIX230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:NRIX230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:NRIX230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:NRIX230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:NRIX230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:NRIX230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:NRIX230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:NRIX230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:NRIX230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:NRIX230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:NRIX230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:NRIX230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:NRIX230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:NRIX230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:NRIX230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:NRIX230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:NRIX230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
O:NRIX230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:NRIX230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:NRIX230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:NRIX230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:NRIX230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:NRIX230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:NRIX230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:NRIX230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:NRIX230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:NRIX230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:NRIX230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients
GlobeNewswire Inc. • 5d ago
Calendar Calendar of Events
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.
GlobeNewswire Inc. • 1w ago
Health Health
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. In addition, and in lieu of common stock, Nurix sold to certain investors pre-funded warrants to purchase 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $188.6 million.
GlobeNewswire Inc. • 1mo ago
Stocks Financing Agreements
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $175.0 million. Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock in connection with the public offering. The offering is expected to close on or about April 16, 2024, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Nurix.
GlobeNewswire Inc. • 1mo ago
Stocks Financing Agreements
Nurix Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions. All of the securities will be offered and sold by Nurix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
GlobeNewswire Inc. • 1mo ago
News News
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 5% and 13.77%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research • 1mo ago
Stocks Earnings Releases and Operating Results
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences
GlobeNewswire Inc. • 1mo ago
Health Health
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement
GlobeNewswire Inc. • 1mo ago
Management Partnerships
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation
GlobeNewswire Inc. • 1mo ago
Analyst Analyst Ratings
Critical Insights From Nurix Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 8 analysts have released ratings for Nurix Therapeutics (NASDAQ:NRIX), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 2 1 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Nurix Therapeutics, presenting an average target of $24.38, a high estimate of $31.00, and a low estimate of $10.00. A 0.08% drop is evident in the current average compared to the previous average price target of $24.40. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive Nurix Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gil Blum Needham Maintains Buy $31.00 $31.00 Gil Blum Needham Maintains Buy $31.00 - Terence Flynn Morgan Stanley Raises Equal-Weight $10.00 $9.00 Robert Burns HC Wainwright & Co. Lowers Buy $19.00 $35.00 Derek Archila Wells Fargo Lowers Overweight $20.00 $23.00 Gregory Renza RBC Capital Lowers Outperform $22.00 $24.00 Gil Blum Needham Maintains Buy $31.00 - Gil Blum Needham Maintains Buy $31.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information provides a snapshot of how ...Full story available on Benzinga.com
Benzinga • 1mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT